Alessandra Tedeschi MD

Alessandra Tedeschi, MD, discusses data from a subgroup analysis of the phase 3 SEQUOIA trial in CLL/SLL.

Alessandra Tedeschi, MD, discusses the utility of zanubrutinib plus venetoclax in patients with CLL/SLL harboring deletion 17p and/or TP53 mutations.

Alessandra Tedeschi, MD, discusses 10-year follow-up data on treatment with first-line ibrutinib in treatment-naive chronic lymphocytic leukemia.

Alessandra Tedeschi MD, Department of Hematology, Azienda Ospedaliera Niguarda Ca' Granda in Milan, Italy, discusses the long-term findings of the phase III RESONATE-2 trial during the 2019 European Hematology Association Congress.